Nova Eye, Inc.
$404.7K 474 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Amarin Pharma Inc.
Amarin Pharma Inc. reported $405,108.15 across General Payments, Research, and Ownership to 300 physicians and teaching hospitals across 302 transactions.
- $405.1K Above-median payer
- All-tracks total
- 302 Above-median volume
- Transactions
- 300 Above-median reach
- Recipients
- −$190.8K
- General Payments vs PY2023
Amarin Pharma Inc. reported $405,108.15 across all CMS Open Payments tracks (General + Research + Ownership) to 300 physicians and teaching hospitals in Program Year 2024 - ranking #817 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $199,294.95, averaging $1.4K per recipient.
How Amarin Pharma Inc.'s $405.1K all-tracks total breaks down
Amarin Pharma Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
22/100
Total payments
F
14/100
Transaction volume
F
12/100
Physician reach
F
12/100
Payment type diversity
D
50/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer amarin-pharma-inc Amarin Pharma Inc.
$405.1K · #817/1,925 · 0.0% industry · PY2024
- TOT $405.1K
- RANK #817
- SHARE 0.0%
- TXN 302
- RCP 300
- CAT 4
- GEN $199.3K
- ΔGEN −$190.8K
- TOP1 36.0%
- PY 2024
Volume peers
Nearest volume peer: Nova Eye, Inc. ($404.7K)
Amarin Pharma Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Amarin Pharma Inc.'s CMS-reported General Payments decreased by $190.8K (−48.9%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: AMARIN PHARMA, INC.PY2023: AMARIN PHARMA, INC.PY2024: Amarin Pharma Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $390,088.35
- PY2024
- $199,294.95
What the Data Shows for Amarin Pharma Inc.
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For Amarin Pharma Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
Of the 4 general-payment categories charted below, "Compensation for Services Other Than Consulting" is the largest at $140.9K across 40 transactions, 70.7% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
"Compensation for Services Other Than Consulting" leads Amarin Pharma Inc.'s 4-category general-payment breakdown at $140.9K, 70.7% of the reported total.
Amarin Pharma Inc. reports 4 general-payment categories - the top three are Compensation for Services Other Than Consulting (70.7%), Travel and Lodging (15.1%), and Food and Beverage (10.6%). The remaining 1 category make up 3.6% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Amarin Pharma Inc. divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Compensation for Services Other Than Consulting | $140.9K | 40 | 70.7% |
| Travel and Lodging | $30.0K | 43 | 15.1% |
| Food and Beverage | $21.1K | 210 | 10.6% |
| Consulting Fee | $7.3K | 7 | 3.6% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $139,630.59 (70.1%) of $199,294.95 in this company's General Payments records across 204 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Amarin Pharma Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Paul Cohen
$71,756.60 across 12 reported transactions
- 2
John Osborne
$42,715.53 across 35 reported transactions
- 3
Payal Kohli
$9,008.06 across 7 reported transactions
- 4
Matthew Budoff
$8,167.30 across 5 reported transactions
- 5
Viet Le
$7,983.10 across 8 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Amarin Pharma Inc.'s spend rank (#817 of 1,925, top 42% by spend) and concentration rank (#775 of 1,838, top 42% most concentrated) land at roughly the same percentile, an unusually proportionate case where payment size and payment concentration move together.
View all 12 companies in this HHI neighborhood as a list
- Air Techniques, Inc. : $23.7K total payments, HHI 1886
- OnMark, Inc. : $93.7K total payments, HHI 1884
- Sechrist Industries Inc : $740.50 total payments, HHI 1882
- Reichert, Inc. : $186.8K total payments, HHI 1880
- Canary Medical USA LLC : $754.5K total payments, HHI 1873
- Avyxa Pharma, LLC : $17.2K total payments, HHI 1863
- Amarin Pharma Inc. (this company) : $199.3K total payments, HHI 1855
- HydroCision, Inc. : $117.1K total payments, HHI 1854
- C. R. Bard, Inc. & Subsidiaries : $865.6K total payments, HHI 1853
- Orchard Therapeutics North America : $14.0K total payments, HHI 1853
- Zest Holdings, LLC : $571.1K total payments, HHI 1849
- Turing Medical Technologies : $128.3K total payments, HHI 1844
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Amarin Pharma Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Amarin Pharma Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Amarin Pharma Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Ivoclar Vivadent, Inc.
$405.7K 1,041 recipients
Compare payment profiles
BlueRock Therapeutics LP
$405.9K 4 recipients
Compare payment profiles
Mizuho America, Inc.
$403.0K 57 recipients
Compare payment profiles
Onkos Surgical, Inc.
$402.3K 461 recipients
Compare payment profiles
Geistlich Pharma, North America, Inc.
$401.7K 2,543 recipients
Compare payment profiles
Put this to use
Amarin Pharma Inc. ranks #817 of 1,925 by all-tracks total payments, led by "Compensation for Services Other Than Consulting".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Compensation for Services Other Than Consulting" spend across every manufacturer, not just Amarin Pharma Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.